Portal de Periódicos da CAPES

On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA

2013; Royal Society of Chemistry; Volume: 138; Issue: 18 Linguagem: Inglês

10.1039/c3an00911d

1364-5528

Maria Serena Chiriacò, Elisabetta Primiceri, Alessandro Montanaro, Francesco Feo, Lorenzo Leone, R. Rinaldi, Giuseppe Maruccio,

Molecular Biology Techniques and Applications

Prostate cancer affects a large part of the western male population. The need for an early and accurate detection is thus a great challenge in common clinical practice, but the lack of specificity of the serum marker PSA (Prostate Specific Antigen) is a serious problem since its increased concentration can be related to several abnormalities. PSA, however, is found in serum in both a free and a complexed form with other proteins and the percentage amount of unbound PSA (the free-to-total PSA ratio) can be employed to distinguish prostate cancer from benign prostatic conditions, and also to predict the future risk of prostate cancer. To improve the operating characteristics of current PSA tests and to provide a clinical tool able to run label-free and sensitive analysis, we thus developed a biosensing platform based on Electrochemical Impedance Spectroscopy (EIS), which allows the contemporary detection of free and total PSA on a single biochip, enabling a quick screening for the risk of prostate cancer thanks to the presence of two different immobilized antibodies specific for the different antigens researched.